|

LEXICON PHARMACEUTICALS INC (LXRX)

US5288723027 - Common Stock

1.15  +0.09 (+8.49%)

After market: 1.12 -0.03 (-2.61%)

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (12/1/2023, 7:09:02 PM)

After market: 1.12 -0.03 (-2.61%)

1.15

+0.09 (+8.49%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)11-08 2023-11-08/bmo
Earnings (Next)02-29 2024-02-29/amc
Ins Owners1.72%
Inst Owners77.05%
Market Cap281.66M
Shares244.92M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts80
IPO04-07 2000-04-07
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

LXRX Daily chart

Company Profile

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 135 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Its LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of SGLT2 in the kidney.

Company Info

LEXICON PHARMACEUTICALS INC

8800 Technology Forest Place, 8800 Technology Forest Place

The Woodlands TEXAS 77381

P: 12818633000.0

CEO: Lonnel Coats

Employees: 135

Website: https://www.lexpharma.com/

LXRX News

News Image2 days ago - Lexicon Pharmaceuticals, Inc.Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid...

News Image10 days ago - Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following...

News Image19 days ago - Lexicon Pharmaceuticals, Inc.INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant...

News Image21 days ago - Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies...

News Image24 days ago - Seeking AlphaLexicon Pharmaceuticals GAAP EPS of -$0.21 in-line, revenue of $0.16M misses by $1.9M (NASDAQ:LXRX)

Lexicon Pharmaceuticals reports Q3 GAAP EPS of -$0.21 in-line, but revenue of $0.16M misses by $1.9M.

News Image24 days ago - Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Commercial launch of INPEFA® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with...

LXRX Twits

Here you can normally see the latest stock twits on LXRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example